These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21109692)

  • 1. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.
    Rumi E; Passamonti F; Elena C; Pietra D; Arcaini L; Astori C; Zibellini S; Boveri E; Pascutto C; Lazzarino M
    Haematologica; 2011 Mar; 96(3):454-8. PubMed ID: 21109692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
    Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
    Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
    Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
    Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
    Anelli L; Zagaria A; Specchia G; Albano F
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
    Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
    Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.
    Andrikovics H; Nahajevszky S; Koszarska M; Meggyesi N; Bors A; Halm G; Lueff S; Lovas N; Matrai Z; Csomor J; Rasonyi R; Egyed M; Varkonyi J; Mikala G; Sipos A; Kozma A; Adam E; Fekete S; Masszi T; Tordai A
    Leukemia; 2010 Oct; 24(10):1809-13. PubMed ID: 20811399
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
    Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
    Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
    Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Siragusa S; Hanson CA; Pardanani A; Tefferi A
    Leukemia; 2010 Apr; 24(4):859-60. PubMed ID: 20111067
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
    Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
    Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
    [No Abstract]   [Full Text] [Related]  

  • 14. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
    Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
    Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies.
    Li SL; Zhang PJ; Sun GX; Lu ZJ
    Ann Hematol; 2014 Nov; 93(11):1845-52. PubMed ID: 25015051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.